Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03467152 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
NCT03467152 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 326 participants.
The verdict
NCT03467152, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
Study Summary
This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Irsenontrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2020-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03467152
The ClinicalTrials.gov registry entry for NCT03467152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03467152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03467152 about?
NCT03467152 is a clinical study titled "Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies". This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies afte...
What is the current status of trial NCT03467152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2018-05-04. Estimated completion is 2020-04-15.
What interventions are being tested in trial NCT03467152?
The interventions under investigation include: Placebo (DRUG), Irsenontrine (DRUG).
Who is sponsoring clinical trial NCT03467152?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.